MTOR and breast carcinoma: Subsequent laboratory studies have focused on comparison of everolimus in combination with endocrine therapies [15, 16] as well as other PI3K/Akt/mTOR inhibitors in a variety of breast cancer cell lines [17, 18] and these studies have reported synergy between tamoxifen or AI therapy and everolimus.